A meta-analysis of 12 randomized controlled trials (n = 17,996) further confirmed these renoprotective effects, with agents structurally closer to endogenous human GLP-1, such as semaglutide, showing the strongest benefit (RR = 0.78, 95% CI: 0.710.85) ( 3.4 Hepatic protection In clinical practice, semaglutide has demonstrated notable efficacy in resolving NASH without aggravating hepatic fibrosis
Mahyar Etminan, senior author, epidemiologist and associate professor in the department of ophthalmology and visual sciences at the UBC faculty of medicine To help fill this knowledge gap, UBC researchers examined health insurance claim records for approximately 16 million U.S
Keeping your prepared medication in a cool, dark placea desk drawer, purse, or bathroom cabinet away from direct sunlightmaintains stability during the active treatment week
Clin Gastroenterol Hepatol